BeiGene Past Earnings Performance
Past criteria checks 0/6
BeiGene's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 42.7% per year.
Key information
-2.7%
Earnings growth rate
7.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 42.7% |
Return on equity | -15.6% |
Net Margin | -16.9% |
Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts
Aug 14BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth
Aug 09BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Jun 21We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation
May 30Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?
Apr 21BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07Revenue & Expenses Breakdown
How BeiGene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,097 | -524 | 1,653 | 1,862 |
31 Mar 24 | 2,763 | -784 | 1,604 | 1,831 |
31 Dec 23 | 2,459 | -882 | 1,505 | 1,779 |
30 Sep 23 | 2,204 | -959 | 1,418 | 2,472 |
30 Jun 23 | 1,811 | -1,732 | 1,376 | 2,472 |
31 Mar 23 | 1,557 | -1,917 | 1,313 | 2,049 |
31 Dec 22 | 1,416 | -2,004 | 1,279 | 1,641 |
30 Sep 22 | 1,250 | -2,149 | 1,257 | 0 |
30 Jun 22 | 1,069 | -2,030 | 1,203 | 0 |
31 Mar 22 | 877 | -1,960 | 1,104 | 0 |
31 Dec 21 | 1,176 | -1,458 | 990 | 1,459 |
30 Sep 21 | 1,062 | -1,340 | 892 | 0 |
30 Jun 21 | 947 | -1,327 | 783 | 0 |
31 Mar 21 | 863 | -1,167 | 675 | 0 |
31 Dec 20 | 309 | -1,625 | 600 | 0 |
30 Sep 20 | 266 | -1,512 | 535 | 0 |
30 Jun 20 | 225 | -1,394 | 479 | 0 |
31 Mar 20 | 402 | -1,145 | 438 | 0 |
31 Dec 19 | 428 | -949 | 388 | 0 |
30 Sep 19 | 430 | -829 | 317 | 0 |
30 Jun 19 | 434 | -665 | 261 | 0 |
31 Mar 19 | 244 | -737 | 224 | 0 |
31 Dec 18 | 198 | -674 | 195 | 0 |
30 Sep 18 | 158 | -505 | 150 | 0 |
30 Jun 18 | 324 | -243 | 117 | 0 |
31 Mar 18 | 271 | -147 | 83 | 0 |
31 Dec 17 | 238 | -93 | 63 | 0 |
30 Sep 17 | 220 | -31 | 44 | -5 |
30 Jun 17 | 0 | -184 | 33 | 0 |
31 Mar 17 | 0 | -148 | 26 | 0 |
31 Dec 16 | 1 | -119 | 20 | 0 |
30 Sep 16 | 6 | -109 | 15 | 5 |
30 Jun 16 | 7 | -87 | 12 | 0 |
31 Mar 16 | 8 | -69 | 9 | 0 |
31 Dec 15 | 9 | -57 | 7 | 0 |
30 Sep 15 | 6 | -34 | 6 | 0 |
30 Jun 15 | 11 | -29 | 8 | 0 |
31 Mar 15 | 12 | -26 | 7 | 0 |
31 Dec 14 | 13 | -18 | 7 | 0 |
31 Dec 13 | 11 | -7 | 3 | 0 |
Quality Earnings: BGNE is currently unprofitable.
Growing Profit Margin: BGNE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.
Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: BGNE has a negative Return on Equity (-15.56%), as it is currently unprofitable.